• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国亨廷顿舞蹈症的死亡率

Huntington's disease mortality in the United States.

作者信息

Lanska D J, Lavine L, Lanska M J, Schoenberg B S

机构信息

Department of Neurology, University Hospitals of Cleveland, OH 44106.

出版信息

Neurology. 1988 May;38(5):769-72. doi: 10.1212/wnl.38.5.769.

DOI:10.1212/wnl.38.5.769
PMID:2966305
Abstract

The first analysis of multiple cause-of-death data for Huntington's disease in the United States was performed, using data from the National Center for Health Statistics for the period 1971 and 1973 through 1978. The overall mortality rate was 2.27 per million population per year, approximately 80% higher than the corresponding rate for deaths in which Huntington's disease was listed as the underlying cause of death. Age-specific mortality rates peaked around age 60. Rates were similar for both sexes, and higher in whites than nonwhites. Age-adjusted rates were similar for United States whites and reported values from the Scandinavian countries. The leading causes of death were pneumonia and heart disease. Other common causes of death were nutritional deficiencies; mental disorders; cerebrovascular disorders; and accidents, poisonings, and violence. Suicide was rarely reported.

摘要

利用美国国家卫生统计中心1971年、1973年至1978年期间的数据,首次对美国亨廷顿舞蹈症的多种死因数据进行了分析。总体死亡率为每年每百万人口2.27人,比将亨廷顿舞蹈症列为根本死因的相应死亡率高出约80%。特定年龄死亡率在60岁左右达到峰值。男女死亡率相似,白人高于非白人。美国白人和斯堪的纳维亚国家报告的年龄调整率相似。主要死因是肺炎和心脏病。其他常见死因包括营养缺乏;精神障碍;脑血管疾病;以及事故、中毒和暴力。自杀报告很少。

相似文献

1
Huntington's disease mortality in the United States.美国亨廷顿舞蹈症的死亡率
Neurology. 1988 May;38(5):769-72. doi: 10.1212/wnl.38.5.769.
2
Conditions associated with Huntington's disease at death. A case-control study.
Arch Neurol. 1988 Aug;45(8):878-80. doi: 10.1001/archneur.1988.00520320068017.
3
Causes of death in patients with Huntington's disease and in unaffected first degree relatives.亨廷顿舞蹈症患者及未患病的一级亲属的死因
J Med Genet. 1992 Dec;29(12):911-4. doi: 10.1136/jmg.29.12.911.
4
CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.美国疾病控制与预防中心国家健康报告:2005 - 2013年美国发病和死亡的主要原因以及相关行为风险和保护因素
MMWR Suppl. 2014 Oct 31;63(4):3-27.
5
Notification of Huntington's disease as primary cause of death in Brazil from 1984 to 2008.1984年至2008年巴西亨廷顿舞蹈症作为主要死因的通报
Genet Mol Res. 2016 Jul 14;15(2):gmr8257. doi: 10.4238/gmr.15028257.
6
Age at Death and Causes of Death in Patients with Huntington Disease in Norway in 1986-2015.1986 - 2015年挪威亨廷顿病患者的死亡年龄及死因
J Huntingtons Dis. 2018;7(1):77-86. doi: 10.3233/JHD-170270.
7
Causes of death in Huntington's disease.亨廷顿舞蹈症的死因
Med J Aust. 1982 Feb 20;1(4):153. doi: 10.5694/j.1326-5377.1982.tb132224.x.
8
Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple-cause mortality data.1979年至1992年美国肺癌死亡情况:基于多病因死亡率数据的分析
Int J Epidemiol. 1998 Apr;27(2):159-66. doi: 10.1093/ije/27.2.159.
9
Suicide risk in Huntington's disease.亨廷顿舞蹈症中的自杀风险。
J Med Genet. 1993 Apr;30(4):293-5. doi: 10.1136/jmg.30.4.293.
10
Deaths: preliminary data for 2002.死亡情况:2002年初步数据。
Natl Vital Stat Rep. 2004 Feb 11;52(13):1-47.

引用本文的文献

1
Disparities in Huntington's disease care and research.亨廷顿舞蹈症护理与研究中的差异。
Curr Opin Neurol. 2025 Aug 1;38(4):337-342. doi: 10.1097/WCO.0000000000001376. Epub 2025 May 21.
2
A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington's Disease in Korea.韩国亨廷顿舞蹈症患者诊断检查及特殊注意事项实用指南。
J Mov Disord. 2025 Jan;18(1):17-30. doi: 10.14802/jmd.24232. Epub 2024 Dec 26.
3
Real-world experience with Deutetrabenazine management in patients with Huntington's disease using video-based telemedicine.
使用基于视频的远程医疗管理亨廷顿病患者的二氢麦角碱的真实世界经验。
Neurol Sci. 2024 May;45(5):2047-2055. doi: 10.1007/s10072-023-07179-9. Epub 2023 Nov 17.
4
Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in .雷帕霉素可减少神经元中突变型亨廷顿蛋白的聚集,并改善其运动能力。
Front Aging Neurosci. 2023 Sep 26;15:1223911. doi: 10.3389/fnagi.2023.1223911. eCollection 2023.
5
Palliative care in advanced Huntington's disease: a scoping review.晚期亨廷顿病的姑息治疗:范围综述。
BMC Palliat Care. 2023 May 3;22(1):54. doi: 10.1186/s12904-023-01171-y.
6
Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.罗格列酮通过纠正亨廷顿病的能量代谢改善心脏和骨骼肌功能障碍。
Cells. 2022 Aug 27;11(17):2662. doi: 10.3390/cells11172662.
7
Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis.2011年至2016年期间一家亨廷顿舞蹈症中心亨廷顿舞蹈症患者的住院情况:一项回顾性分析
Mov Disord Clin Pract. 2022 May 5;9(5):628-636. doi: 10.1002/mdc3.13459. eCollection 2022 Jul.
8
Targeted Genetic Reduction of Mutant Huntingtin Lessens Cardiac Pathology in the BACHD Mouse Model of Huntington's Disease.在亨廷顿舞蹈症的BACHD小鼠模型中,对突变型亨廷顿蛋白进行靶向基因敲减可减轻心脏病理变化。
Front Cardiovasc Med. 2021 Dec 24;8:810810. doi: 10.3389/fcvm.2021.810810. eCollection 2021.
9
Metabolism in Huntington's disease: a major contributor to pathology.亨廷顿病中的代谢:病理学的主要贡献因素。
Metab Brain Dis. 2022 Aug;37(6):1757-1771. doi: 10.1007/s11011-021-00844-y. Epub 2021 Oct 27.
10
New Avenues for the Treatment of Huntington's Disease.治疗亨廷顿病的新途径。
Int J Mol Sci. 2021 Aug 4;22(16):8363. doi: 10.3390/ijms22168363.